In the changing New Health environment, Market Access has become a focus area for pharmaceutical companies. With more stakeholders involved in the decision process, companies need to prove the value for their products along the lifecycle. What does it take to maximize Market Access? It involved the integration of key drivers, including:

  • The right strategy to plan early on for market demands, incorporating commercial endpoints in clinical development
  • The right evidence to meet stakeholder requirements, in both registrational and post-marketing research
  • The right relationships – the knowledge and understanding needed to reach local decision-makers who adopt prescribe and reimburse a product